EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Mechanical Thrombectomy Versus Anticoagulation in Intermediate‐Risk Pulmonary Embolism: A Risk‐Stratified, Propensity Score–Matched Analysis

Fouad Hanna iD, Ahmed Abdelmaksoud, Ali Dway iD, Abdelrahman El-Helbawy, David C Kaelber, Habib Rehman Khan iD, Noha Hammad iD, Amr Mohsen, Mina Basta

Catheterization and Cardiovascular Interventions · 2026-08 · 108 (2) · 489-504

DOI: 10.1002/ccd.70676 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Catheterization and Cardiovascular Interventions, online erschienen am 31.05.2026. Verfasst von Fouad Hanna und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Cairo University, Giza, Egypt. Hauptthemen laut MEDLINE: Pulmonary Embolism, Anticoagulants, Thrombectomy. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To compare 1‐year all‐cause mortality and long‐term cardiopulmonary outcomes in intermediate‐risk pulmonary embolism (PE) treated with mechanical thrombectomy (MT) versus anticoagulation (AC).

Background

Whether MT confers a survival advantage—and whether this benefit differs across intermediate risk PE subgroups remains unknown.

Methods

Retrospective, 1:1 propensity score–matched cohort study using the TriNetX Analytics Network (2010–2026). Adults with acute PE were stratified into low‐intermediate (corresponding to AHA/ACC PE Category C1–C2 in the 2026 AHA/ACC PE Guideline) and high‐intermediate (corresponding to AHA/ACC PE Category C3) risk subgroups. The primary endpoint was all‐cause mortality at 365 days. Secondary endpoints included new‐onset pulmonary hypertension, right heart failure, acute respiratory failure, and bleeding. IRB waiver was applicable per HIPAA de‐identification standards.

Results

After matching, 2717 patients per arm were included in the low‐intermediate risk cohort and 1150 per arm in the high‐intermediate risk cohort. MT was associated with lower 1‐year all‐cause mortality in both subgroups: low‐intermediate risk (11.0% vs. 17.8%; HR 0.642 [95% CI 0.556–0.741]; p < 0.001) and high‐intermediate risk (7.0% vs. 11.0%; HR 0.631 [95% CI 0.475–0.839]; p = 0.002). In low‐intermediate risk PE, MT was associated with increased pulmonary hypertension (HR 1.578; p < 0.001) and right heart failure (HR 4.473; p < 0.001). In high‐intermediate risk PE, MT reduced pulmonary hypertension (HR 0.764; p = 0.044) and bleeding (HR 0.744; p = 0.048).

Conclusions

MT was associated with reduced 1‐year mortality compared with AC alone in intermediate‐risk PE. The net clinical benefit is risk‐profile dependent: MT appears favorable in high‐intermediate risk (AHA/ACC Category C3‐equivalent) PE, whereas in low‐intermediate risk (AHA/ACC Category C1–C2‐equivalent) PE the apparent survival advantage is offset by elevated rates of pulmonary hypertension and right heart failure. These findings are hypothesis‐generating and require validation in adequately powered randomized controlled trials with pre‐specified long‐term mortality endpoints.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary EmbolismAnticoagulantsThrombectomyHumansFemaleRetrospective StudiesRisk FactorsRisk AssessmentTreatment OutcomeMaleAgedTime FactorsPropensity ScoreMiddle AgedAged, 80 and over

Stichwörter der Autor:innen

2026 AHA/ACC PE guidelineanticoagulationhigh‐intermediate risklow‐intermediate riskmechanical thrombectomypropensity score matchingpulmonary embolismpulmonary embolism response team

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Faculty of Medicine, Cairo University, Giza, Egypt.
  • Department of Internal Medicine, University of California, Riverside, California, USA.
  • Al-Andalus University for Medical Sciences, Tartus, Syria.
  • Faculty of Medicine, Helwan University, Cairo, Egypt.
  • Center for Clinical Informatics Research and Education, The MetroHealth System, Cleveland, Ohio, USA.
  • London Health Sciences Centre Research Institute, Western University, London, Ontario, Canada.

ORCID-Profile: Fouad Hanna, Ali Dway, Habib Rehman Khan, Noha Hammad

Zitieren

APA

Hanna, F., Abdelmaksoud, A., Dway, A., El-Helbawy, A., Kaelber, D. C., Khan, H. R., Hammad, N., Mohsen, A., & Basta, M. (2026). Mechanical Thrombectomy Versus Anticoagulation in Intermediate‐Risk Pulmonary Embolism: A Risk‐Stratified, Propensity Score–Matched Analysis. Catheterization and Cardiovascular Interventions, 108(2), 489-504. https://doi.org/10.1002/ccd.70676

Vancouver

Hanna F, Abdelmaksoud A, Dway A, El-Helbawy A, Kaelber DC, Khan HR, et al. Mechanical Thrombectomy Versus Anticoagulation in Intermediate‐Risk Pulmonary Embolism: A Risk‐Stratified, Propensity Score–Matched Analysis. Catheterization and Cardiovascular Interventions. 2026;108(2):489-504. doi:10.1002/ccd.70676

BibTeX
@article{Hanna2026,
  author = {Hanna, Fouad and Abdelmaksoud, Ahmed and Dway, Ali and El-Helbawy, Abdelrahman and Kaelber, David C and Khan, Habib Rehman and Hammad, Noha and Mohsen, Amr and Basta, Mina},
  title = {Mechanical Thrombectomy Versus Anticoagulation in Intermediate‐Risk Pulmonary Embolism: A Risk‐Stratified, Propensity Score–Matched Analysis},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2026},
  volume = {108},
  number = {2},
  pages = {489--504},
  doi = {10.1002/ccd.70676}
}
Kostenlos starten →